Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: A gait analysis system is disclosed. Some implementations of the gait analysis system include instrumented footwear including mobile sensors, a processor, a computer-readable data storage device storing program instructions. The program instructions can control the system to perform operations, including, determining gait information of a user performing a test routine, using the instrumented footwear. The operations can also include determining gait parameters based on the gait information. The operations can also include determining gait symmetry of the user based on the gait parameters. The operations can also include determining a gait signature of the user based on the gait parameters. The operations can also include determining a treatment effect based on the gait signature.

Abstract: A gait analysis system is disclosed. Some implementations of the gait analysis system include instrumented footwear including mobile sensors, a processor, a computer-readable data storage device storing program instructions. The program instructions can control the system to perform operations, including, determining gait information of a user performing a test routine, using the instrumented footwear. The operations can also include determining gait parameters based on the gait information. The operations can also include determining gait symmetry of the user based on the gait parameters. The operations can also include determining a gait signature of the user based on the gait parameters. The operations can also include determining a treatment effect based on the gait signature.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Systems and techniques disclosed herein include receiving static device data in response to detected first biometric movements, receiving mobile device data in response to detected second biometric movements, applying an analysis algorithm to the static data to determine static attributes, applying the analysis algorithm to the mobile data to determine mobile attributes, comparing the static attributes to the mobile attributes, and determining a modification action based on the comparing. A mobile device may be validated based on the determining that the static attributes are within a threshold parameter of the mobile attributes.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: The present disclosure provides methods of identifying a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of identifying a subject having a disease or condition suitable for treatment with dupilumab. The present disclosure also provides methods of carrying out a clinical trial for dupilumab treatment of a disease or condition.

Abstract: Methods for treating or preventing allergic asthma and associated conditions in a subject are provided. Certain methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody. Other methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4R (IL-4R) antagonist, such as an anti-IL-4R antibody. Still other methods disclosed here comprise administering to a subject in need thereof a first therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody, and a second therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. Allergic asthma-associated signature genes are provided. Methods of altering (e.g.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: The present disclosure provides methods for receiving distinct electrical signals generated based on a body part, generating a plurality of extracted features based on the distinct electrical signals, identify clinically relevant features from the plurality of extracted features, wherein the clinically relevant features meet a threshold determined based on a clinical outcome.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

Abstract: Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.